Top

BMC Health Services Research

Published in:

Open Access 01-12-2019 | Atorvastatin | Research article

Аn affordability of statins therapy - comparative analysis between Ukraine and Bulgaria

Authors: Oksana Tkachova, Larysa Iakovlieva, Zornitsa Mitkova, Manoela Manova, Alexandra Savova, Guenka Petrova

Published in: BMC Health Services Research | Issue 1/2019

Abstract

Background

The statins are а developing group of cardiovascular medicines, widely used for dyslipidemia. As a whole statins consumption leads to reduction in cardiovascular events and death, and improves the disease control. The main study issue considers the differences in an affordability to lipid lowering medicines in the countries with the highest morbidity and mortally rate within and outside EU. The affordability has been researched by exploring the price differences and average wages.

Methods

On total 7 international nonproprietary names and 19 dosage forms available on both markets are observed during 2013–2016. An average, minimum, and maximum retail prices per DDD, standard deviation (SD) has been calculated for all marketed dosage forms. A price ratio between the minimal and maximal price per DDD is estimated in order to evaluate their difference. Affordability of the treatment is determined as the number of working hours per month needed for patient to purchase medicines for a monthly therapy.

Results

Large variations of price per DDD, SD and the average price exist between different dosage forms in both countries. The highest value of a price ratio is observed for 5 mg rosuvastatin in Bulgaria and 10 mg rosuvastatin in Ukraine.

The number of working hours needed to cover monthly therapy has increased during 2013–2016 in Ukraine. The most affordable is treatment with a generic atorvastatin in Bulgaria and generic rosuvastatin in Ukraine. The most expensive rosuvastatin in Bulgaria and atorvastatin in Ukraine are found as the least affordable for a monthly therapy.

Conclusions

The decrease of prices for statins is not the only reason influencing patients’ affordability to therapy for statin therapy in Ukraine and Bulgaria. The difference in affordability in Ukraine and Bulgaria is affected mainly by the economic development in the country as well as wages variation.

Kapur NK, Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag. 2008;4(2):341–53.CrossRefPubMedPubMedCentral

Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D, Luo D. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med. 1999;159(15):1793–802 https://www.ncbi.nlm.nih.gov/pubmed/10448784.CrossRefPubMed

Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, Leal J, Luengo-Fernandez R, Burns R, Rayner M, Townsend N. European cardiovascular disease statistics 2017. Brussels: European Heart Network; 2017. Available from: http://www.ehnheart.org/images/CVD-statistics-report-August-2017.pdf

Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Cholesterol Treatment Trialists' (CTT) Collaborators. Lancet. 2012;380(9841):581–90. https://doi.org/10.1016/S0140-6736(12)60367-5.CrossRefPubMed

Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am CollCardiol. 2008;52:1769–81.CrossRef

Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, KeechCholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–405. https://doi.org/10.1016/S0140-6736(14)61368-4.CrossRefPubMed

Tian J, Gu X, Sun Y, Ban X, Xiao Y, Hu S, Yu B. Effect of statin therapy on the progression of coronary atherosclerosis. BMC Cardiovasc Disord. 2012;12:70. https://doi.org/10.1186/1471-2261-12-70.CrossRefPubMedPubMedCentral

Manova M, Stoimenova A, Savova A, Peikov P, Petrova G. Utilization and price trends in some reimbursed cardiovascular medicines. Biotechnol. 2011;25(2):2424–31. https://doi.org/10.5504/BBEQ.2011.0033.CrossRef

Iakovlieva L, Tkachova O, Mishchenko O, Gerasymova O, Bezditko N, Kyrychenko O, Matyashova N. Analysis of affordability and consumption of statins in Ukraine in 2015. Value in Health. 2016;19(7):A347–930.

10.

Bezditko N,Mischenko O, Chynush I,Adonkina V, Bondarchuk І. Opportunities unused: pharmacoepidemiologicalanalisysofstatinsusagedimanicsinUkraine. Clinical Pharmacy 2014;l (2): 62–65. Available from:http://nuph.edu.ua/zhurnal-klinichna-farmaciya-2014-tom-19-2/

11.

World Health Organization 2003. Adherence to long-term therapies:evidence for action. Noncomunicable diseases and mental health adherence to long-term therapies project. Available at: http://www.who.int/chp/knowledge/publications/adherence_report/en/

12.

Maningat P, Gordon B, Breslow J. How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy? Curr Atheroscler Rep. 2013;15(1):291. https://doi.org/10.1007/s11883-012-0291-7.CrossRefPubMedCentralPubMed

13.

Catapano AL, Graham I, Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC/EAS guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37:2999–3058.CrossRefPubMed

14.

Zaprutko T, Kopciuch D, Kus K, Merks P, Nowicka M, Augustyniak I, et al. Affordability of medicines in the European Union. PLoS One. 2017;12(2):e0172753. https://doi.org/10.1371/journal.pone.0172753.CrossRefPubMedPubMedCentral

15.

WHO. Measuring medicine prices, availability, affordability and price components, 2nd Edition. World Health Organization and Health Action International 2008 . Available from: http://www.who.int/medicines/areas/access/OMS_Medicine_prices.pdf

16.

Cameron A, Ewen M, Auton M, Abegunde D, The world medicines situation. Medicines prices, availability and affordability. Geneva: World Health Organization; 2011. WHO/EMP/MIE/2011.2.1Available from: http://www.who.int/medicines/areas/policy/world_medicines_situation/WMS_ch6_wPricing_v6.pdf

17.

Angell B, Laba T, Lung T, Brown A, Eades S, Usherwood T, Peiris D. Healthcare expenditure on Indigenous and non-Indigenous Australians at high risk of cardiovascular disease. Int J Equity Health. 2017;16(1):108. https://doi.org/10.1186/s12939-017-0610-2.CrossRefPubMedPubMedCentral

18.

The National Council on Prices and Reimbursement of Medicinal Products in Bulgaria. Annex 1 to PDL. http://ncpr.bg/en. Accessed 1 June 2017.

19.

Soft ware complex "Pharmacy" company "Morion". Mode of access to the site. http://pharmbase.com.ua/poisk/. Accessed 1 June 2017.

20.

Zeng W. A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China. BMC Health Serv Res. 2013;13:390. https://doi.org/10.1186/1472-6963-13-390.CrossRefPubMedCentralPubMed

21.

Jamshed S, Babar Z, Ibrahim M. Generic medicines as a way to improve access and affordability: a proposed framework for Pakistan. J Clin Diagn Res. 2009;3:1596–600.

22.

Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373(9659):240–9. https://doi.org/10.1016/S0140-6736(08)61762-6.CrossRefPubMed

23.

Nicolosi E, Gray AL. Potential costs savings from generic medicines – protecting the prescribed minimum benefits. S Afr Fam Pract. 2009;51(1):59–63.

24.

Lallan H, Borde M, Ray I, Deshmukh Y. Cost variation study of antidiabetics: Indian scenario. Indian J Appl Res. 2014;4(5):420–1.CrossRef

25.

Wagle L, Swamy K, Kempegowda M. Cost variation study of antiepileptic drugs available in India. Аsian J Pharm Clin Res. 2016;9(02):64–8.

26.

Bondar A, Zamikhovska Z. Review of Legal Regulation of Pharma Market of 2016. Outcomes in 2017. The Ukrainian Journal of Business Law.Accessed 03 Mar 2017. Available from:http://www.ujbl.info/article.php?id=919

27.

Demianiuk O. Ukraine Overhauls Pricing Regulatory Framework for Pharmaceuticals. Accessed 10 April 2017. Available from:http://www.bakermckenzie.com/en/insight/ publications/2017/04/recast-regulatory-framework-pharmaceuticals/

28.

Interfax. The Ministry of Health will set new reference prices. Ukraine. Accessed 2017 July 16. Available from http://en.interfax.com.ua/news/general/429450.html

29.

Ryvak T, Makukh K, Zimenkovsky A. Assessment of Drug Adherence Level According to the Patients’ Opinion: Results of Research in Lviv of Ukraine. J Appl Pharma Sci. 2017;7(04):149–56 Available online at http://www.japsonline.com.

30.

Petkova V. Physicians, pharmacists and patients' compliance with chronic treatment in Bulgaria. Pharmacoepidemiol Drug Saf. 2006;15(8):607–12.CrossRefPubMed

31.

National Statistical Institute of Bulgaria. Incomes, expenditures and consumption by households in 2016–2017. Available at: https://www.nsi.bg/en/content/5640/households-income-expenditure-and-consumption. Accessed May 2017.

32.

World Economic Outlook Database-April 2017, International Monetary Fund. Accessed 18 Apr 2017. Available at:https://www.imf.org/external/pubs/ft/weo/2017/01/weodata/index.aspx

33.

Mitkova Z, Manova M. PetrovaG. Relationship between generic competition and generic utilization of cardiovascular medicines monoproducts in Bulgaria. Farmacia. 2016;63(4):3–14.

34.

Babar Z, Ibrahim M, Singh H, Bukahri N, Creese A. Evaluating drug prices, availability, affordability, and Price components: implications for access to drugs in Malaysia. PLoS Med. 2007 Mar;4(3):e82. https://doi.org/10.1371/journal.pmed.0040082.CrossRefPubMedPubMedCentral

35.

Van Mourik MS, Cameron A, Ewen M, Laing RO. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord. 2010;10:25. https://doi.org/10.1186/1471-2261-10-25.CrossRefPubMedPubMedCentral

36.

Ferrario A, Chitan E, Seicas R, Sautenkova N, Bezverhni Z, Kluge H, Habicht J. Progress in increasing affordability of medicines for non-communicable diseases since the introduction of mandatory health insurance in the Republic of Moldova. Health Policy Plan. 2016;31(6):793–800. https://doi.org/10.1093/heapol/czv136.CrossRefPubMedPubMedCentral

Title: Аn affordability of statins therapy - comparative analysis between Ukraine and Bulgaria
Authors: Oksana Tkachova
Larysa Iakovlieva
Zornitsa Mitkova
Manoela Manova
Alexandra Savova
Guenka Petrova
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Atorvastatin
Statins
Simvastatin
Rosuvastatin
Published in: BMC Health Services Research / Issue 1/2019
Electronic ISSN: 1472-6963
DOI: https://doi.org/10.1186/s12913-019-4736-3

At a glance: The STEP trials

Springer Medicine

Аn affordability of statins therapy - comparative analysis between Ukraine and Bulgaria

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Can quality improvement improve the quality of care? A systematic review of reported effects and methodological rigor in plan-do-study-act projects

Barriers and facilitators with medication use during the transition from hospital to home: a qualitative study among patients

Employees’ perceptions of patient safety culture in Norwegian nursing homes and home care services

Multi-level models for heart failure patients’ 30-day mortality and readmission rates: the relation between patient and hospital factors in administrative data

Identifying the key features and outcomes of family navigation services for mental health and/or addictions concerns: a Delphi study

Exploring the solutions to the inherent perils of (the multitude of) guidelines – a focus group study of stakeholders’ perceptions